Safety and Efficacy of T8 on Treating Chronic Abnormal Immune Activation in AIDS Patients
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- AIDS
- Chronic Abnormal Immune Activation
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Double (Participant, Investigator)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 65 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04084444
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Taisheng Li, PhD Peking Union Medical College Hospital
Get Well Soon